Bernstein upgraded Natera to Outperform from Market Perform with a $120 price target. The analyst says the stock’s growth trajectory “isn’t in remission yet.” The stock’s risk/reward “skews greatly to the upside,” the analyst tells investors in a research note. The firm sees the guideline inclusion for 22q and carrier screening, and a more positive evolution of Signatera prices as potential upside catalysts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera launches Alliance A032103 utilizing Signatera MRD test for MIUC
- Natera announces CIRCULATE-PRODIGE-70 study in France
- Updated KDIGO guidelines a catalyst for Natera, says Piper Sandler
- Natera price target raised to $110 from $70 at Piper Sandler
- New Share Price & Shareholder Rights Risk for Natera Inc. – What’s the Latest?
